Introduction
The TNM staging system was developed and has been maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control since 1959. 1 It is the most commonly used staging system by medical professionals around the world, developed as a tool for doctors to discuss the prognosis of newly diagnosed cancer patients, design a treatment plan for individual patients, and standardize comparison between patients participating in clinical trials.
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shao et al Breast cancer has been staged using the AJCC TNM staging system since the 1st edition cancer staging system in 1977 2 based on anatomic factors: the extent of the primary tumor (T), the extent of spread to the regional lymph nodes (N), and the presence of metastasis (M). Scientific developments, 3, 4 especially the understanding of biological markers such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and their close relationship with prognosis, selection of therapy, and response to therapy, have led to the purely anatomic TNM staging for breast cancer being challenged. 5 The National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), 6 European Group on Tumor Markers (EGTM), 7 and the St. Gallen International Expert Consensus 8 recommend the determination of ER, PR, and HER2 status in all breast cancer patients for prognosis and for treatment planning. Another important and widely accepted prognostic factor in breast cancer is the histological grade, standardized by the Nottingham group. [9] [10] [11] Recently, results from prospective clinical trials using multigene panel testing 12, 13 have demonstrated the value of multigene panels for selected patient management and, for one panel at least, 13 have been incorporated into guidelines for treatment by ASCO 6 and NCCN (Breast Cancer Version 2.2017; https:// www.nccn.org/professionals/physician_gls/pdf/breast.pdf, Accessed August 1, 2017).
Consequently, based on evidence available from the peer-reviewed literature 5, 14 and on findings from large but unpublished data sets, 1 new "prognostic stage groups" including grade, ER, PR, HER2, and multigene testing were incorporated into the 8th edition of the AJCC breast cancer staging system to further refine prognostic information.
However, there has not yet been level I evidence to support the 8th edition of the AJCC breast cancer staging system. The primary objective of this study was to compare the two staging systems for prognostic precision using patient information extracted from the Surveillance, Epidemiology and End Results (SEER) research database.
Materials and methods study population and characteristics
The SEER*Stat version 8.3.4 was freely used to extract data from the SEER 18 registries research data online, including data from 1973 to 2014. We could not determine whether surgery was the first intervention, since information about neoadjuvant chemotherapy in the SEER database is lacking.
Because this database does not include detailed information on HER2 status before 2010, patients were limited to those with histologically confirmed unilateral primary breast cancer diagnosed from 2010 to 2014 with complete follow-up until December 2014 (n=383,355). Patients with a history of prior or subsequent in situ or invasive cancer of any type (n=101,432) or patients who were only initially identified by autopsy or death certificate (n=38) were excluded from the study. Patients with unknown AJCC 7 T category, N category, M category, stage group or unknown grade, ER, PR, and HER2 status (n=81,192) were excluded. The stage 0 (n=5,382) and IV (n=7,235) were also excluded because there was no change between the AJCC 7 staging system and AJCC 8 prognostic staging system. Other exclusions were of those patients with no surgery performed on the primary site (n=1,385) or surgery unknown (n=1,421) and those of unknown age (n=15) or unknown race/ethnicity (n=991). Patients were categorized according to the 7th AJCC staging system and the 8th AJCC prognostic staging system. The following patient characteristics were included: date of diagnosis, sex, breast subtype, cause of death, and survival months.
statistical analysis
Breast cancer-specific survival (BCSS) was defined as the date of diagnosis to the date of death attributed to breast cancer. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. Patients who were alive at the study cutoff data were censored.
Categorical variables were analyzed using the chi-squared test, and continuous variables were analyzed using the t-test. The Kaplan-Meier method was used to generate survival curves, and the log-rank test was performed to assess the differences in BCSS and OS between the stages. Multivariable analysis was performed using the Cox proportional hazards regression analysis to identify factors independently associated with outcome. In addition, Akaike's information criterion (AIC) was calculated to estimate how well the staging system fitted the data and the complexity of the model, with a low AIC suggesting a more precise prognostic staging system. Age at diagnosis was included in the model. Results are expressed in HRs and 95% CIs. All tests were two-sided and P-values <0.05 considered statistically significant. Statistical analyses were performed using SAS, version 9.4, software.
Results
A total of 184,221 primary breast cancer patients were identified in the 7th AJCC staging system. However, 16 (Table S5 ). These results demonstrated that the prognostic accuracy of the 8th AJCC prognostic staging system utilizing tumor grade, ER, PR, and HER2 status as biologic staging factors could be considered superior to the 7th staging system.
Univariate analysis demonstrated that patients with stage IIIB had a worse prognosis than those with stage IIIC within the 7th AJCC staging system (long-rank tests, P<0.001), at a median follow-up of 25 months (range, 0-59 months) ( Figure  1 ). Three-year BCSS and OS rates by stage (Table 4) indicate that the 3-year survival for stage IIIB was inferior to stage In order to further consider the prognostic accuracy of the 8th AJCC prognostic staging system, every stage in the 7th AJCC was randomly separated into two parts; 80% patients were staged according to the 8th AJCC prognostic staging system and the other 20% patients using the 7th stage as the reference. 15 BCSS survival curves for stages according to the 8th AJCC prognostic staging system demonstrated that, as expected, the BCSS rates improved in the lower stages and worsened as the stage increased (Figure 2 ). For OS, the estimates were similar ( Figure S1 ). The 3-year BCSS and OS rates according to stage are shown in Abbreviations: AJCC, American Joint Committee on Cancer; OS, overall survival; BCSS, breast cancer-specific survival. Number at risk Number at risk When adjusted for the age at diagnosis, the 8th AJCC prognostic staging system that included grade, ER, PR, and HER2 status had a lower AIC than the 7th AJCC staging system (Table 6) system yielded more precise prognostic information and performed as a superior staging system. Unexpectedly, stage IB patients had a worse prognosis than IIA and IIB in the 8th AJCC ( Figure 2E and Table 5 ); stage IIIA in the 7th AJCC migrated to IB (3-year BCSS, 94.2%) and this patient group had a worse prognosis than IIA (3-year BCSS, 97.7%) or IIB (3-year BCSS, 95.6%) in the 8th prognostic staging system. This phenomenon was not found in stage IIA and IIB patients in the 7th staging system restaged to IB in the 8th staging system ( Figure 2C , D and Table 5 ).
Discussion
The 8th AJCC prognostic staging system for breast cancer builds upon the 7th AJCC but incorporates biological factors peer-reviewed 5 and unpublished data from 238,265 patients diagnosed with invasive breast cancer from 2010 to 2011 in the US National Cancer Database. 16 This population-based (SEER) study examined 168,076 primary breast cancer patients, directly compared the two staging systems, and confirmed the prognostic accuracy of the 8th AJCC prognostic staging system (incorporating tumor grade, ER, PR, and HER2 status as staging biologic factors) was superior to the 7th AJCC staging system. Abdel-Rahman also reported the improvement in the discriminatory value for the 8th AJCC prognostic staging system compared to the anatomical staging system using the patient information extracted from the SEER research database. 17 When we get the updated version of the 8th AJCC prognostic staging system, the uncategorized 16,145 (8.8%) patients could be restaged according to the updated version (Table S8) . We analyzed all again and got the same results. 1) Three-year BCSS and OS rates by stage indicate the 3-year survival for stage IIIB was still inferior to stage IIIC in the 7th AJCC staging system. This inconsistency was not reproduced in the 8th AJCC prognostic staging system ( Figure S2 ). 2) Stage IIIA in the 7th AJCC migrated to IB, and this patient group had a worse prognosis than IIA or IIB in the 8th prognostic staging system ( Figure S3 ). Prior, smaller, studies including SEER data successfully incorporated grade, ER status, and HER2 to refine patient stratification with respect to prognosis. 5 Others have incorporated the triple negative phenotype (ER, PR, and HER2 all negative) to upstage the anatomic staging groups of the TNM and in doing so improved the prognostic accuracy of breast cancer staging. 18 In the 7th AJCC staging system, the stage IIIB has an inferior prognosis than IIIC for BCSS and OS (Table 4 and Figure 1 ). As shown in Table S6 , ER negative (IIIB 33.5% vs IIIC 26.4%), PR negative (IIIB 46.2% vs IIIC 24.6%), HER2 positive (IIIB 26.6% vs IIIC 23.0%), ER negative/PR negative (IIIB 31.4% vs IIIC 24.9%), and ER negative/PR negative/HER2 negative (IIIB 20.9% vs IIIC 16.1%) were mainly distributed in stage IIIB. However, these factors were independent risk factors for BCSS and OS (Table S7) . Evidence from the current analyses evaluating the 7th AJCC staging system (Table 4 and Figure 1,   Table S6, Table S7 ) demonstrated the improved prognostic staging through incorporating these biological factors into the 8th AJCC system.
It has been suggested that the new staging system results in a restaging of a substantial proportion (41%) of patients to a different stage group thus improving the grouping of patients with a similar prognosis.
14 In our study, 53.2% patients were restaged to a different stage group using the 8th AJCC. However, it is unfortunate that 16,145 cases could not be restaged according to the 8th AJCC prognostic staging system (Table S1 ). Some 58.7% cases were T2N1M0-stage IIB in the 7th AJCC, and ER positive, PR positive and HER2 negative. Any impact of this dissonance in clinical practice and trial comparisons remains to be seen.
Although Abdel-Rahman reported the similar results with our analysis, 17 he missed reporting the paradoxical phenomenon that stage IIIA patients in the 7th staging sys- Figure 2 The AJCC staging systems predict breast cancer-specific survival for primary breast cancer patients and indicate the proportion of patients at risk. Notes: in order to further estimate the prognostic accuracy of the 8th aJCC prognostic staging system, patients from every stage in the 7th aJCC were randomly separated into two parts: 80% patients were staged according to the 8th aJCC prognostic staging system and the other 20% patients were the 7th stage as the reference. tem who migrated to stage IB had worse but not superior prognosis than IIA and IIB patients in the 8th staging system ( Figure 2E and Table 5 ). Patients considered stage IIIA in the 7th staging system (ER positive/PR positive/HER2 positive and grade 1-2) migrated to stage IB (3-year BCSS, 94.2%) with a worse prognosis than IIA (3-year BCSS, 97.7%) and IIB (3-year BCSS, 95.6%) in the 8th staging system. Those moving from stage IIIA to IIA or IIB (n=5,739) included ER-positive/PR-positive/HER2-negative, grade 1-2 patients (86.6%) and ER-positive/PR-positive/HER2-positive and grade 3 patients (13.4%). As shown in Table S7 , the ER-positive/PR-positive/HER2-negative patients have a relatively superior prognosis to the ER-positive/PR-positive/ HER2-positve patients with the identical TNM stage and tumor grade. However, the impact of HER2-targeted therapy 19 and consideration of the increasing use of neoadjuvant therapy, particularly for HER2 and triple negative breast cancer, may necessitate merit further refinement of AJCC staging in future. Another needed further refinement of AJCC prognostic staging system was the stage IV group; a small retrospective study identified that triple negative breast cancer had worse OS than ER-positive and HER2-negative carcinomas among M1 patients. 20 It suggested that separating stage IV patients according to biomarkers (ER, PR, and HER2) makes sense.
Recognized limitations of using SEER data include the geographical origins and missing data points, particularly in this comparison the Oncotype Dx ® recurrence score. In the 8th AJCC prognostic staging system, patients with T1-2N0M0, who were ER positive and HER2 negative, and with an Oncotype Dx ® recurrence score <11 should be staged as stage I, given the strong published evidence. 13, 21 Future comparisons using SEER data may be possible to confirm this element of the 8th AJCC.
Conclusion
This comparison of the prognostic accuracy of the 8th AJCC prognostic staging system to the 7th staging system using data from over 168,000 breast cancer patients confirms the enhanced value of the 8th AJCC. However, nuances of the modified staging, gene panel testing and influences of current therapies will require ongoing re-evaluation of the staging system.
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